glp 1 trials Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025) Many people remain excluded from
Description
Eli Lilly: Tirzepatide/Mounjaro Lily initially developed Tirzepatide as a dual agonist, with a half-life of around 5 days, for the treatment of T2DM
Wegovys Low Barrier: Wegovy offers an even lower entry point, with its $199 introductory offer and $349 ongoing price
Future therapies for obesity
A review published in the journal Metabolism found berberine demonstrated meaningful effects on fasting blood glucose and HbA1c in specific study populations
Sleep issues affect about 12% of users
doi:10.1016/j.regpep.2012.12.012 45
